LLY - יחס חוב להיוון בספרים Eli Lilly & Co.

Brilliant R&D leadership strategy has secured Eli Lilly and Company (LLY) a leadership position in obesity therapy. A powerful patent moat guarantees superprofits, while colossal demand enables the company to exercise significant pricing power. The dynamic trend of financial leverage on the balance sheet visualizes the balance between debt and equity, where the final indicator 1.66 expresses the state of the company's debt load metric.

For the defensive, non-cyclical pharmaceutical business of Eli Lilly and Company (LLY), the leverage chart—debt to book capitalization—serves as an indicator of financial strategy resilience. The ratio of total liabilities to equity determines the extent to which the company's growth depends on borrowed funds, where a lower coefficient minimizes credit risks but may limit the pace of expansion.